Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, February 27, 2020
[ Thu, Feb 27th 2020
] - WOPRAI
Wed, February 26, 2020
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
[ Wed, Feb 26th 2020
] - WOPRAI
Raghuram Selvaraju Reiterated (BTAI) at Strong Buy with Increased Target to $95 on, Feb 26th, 2020
Raghuram Selvaraju of HC Wainwright & Co., Reiterated "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $30 to $95 on, Feb 26th, 2020.
Raghuram has made no other calls on BTAI in the last 4 months.
There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Raghuram's Rating of Hold.
This is the rating of the analyst that currently disagrees with Raghuram
- Robyn Karnauskas of "SunTrust Robinson Humphrey" Maintained at Strong Buy with Increased Target to $150 on, Friday, February 14th, 2020
Similar Stocks and Investing Articles
[ Fri, Feb 14th 2020
] - WOPRAI
[ Fri, Feb 14th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 10th 2020
] - WOPRAI
[ Mon, Feb 03rd 2020
] - WOPRAI
[ Fri, Jan 17th 2020
] - WOPRAI
[ Wed, Jan 08th 2020
] - WOPRAI
[ Mon, Dec 30th 2019
] - WOPRAI
[ Tue, Dec 17th 2019
] - WOPRAI
[ Fri, Jan 26th 2018
] - WOPRAI